REGENERON PHARMACEUTICALS, INC. Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security
REGENERON PHARMACEUTICALS, INC. (REGN) reported Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities · last filed 2019-02-07
- REGENERON PHARMACEUTICALS, INC. repayment of long-term debt, long-term lease obligation, and capital security for the quarter ending 2018-12-31 was $0.00.
- REGENERON PHARMACEUTICALS, INC. repayment of long-term debt, long-term lease obligation, and capital security for the quarter ending 2018-09-30 was $0.00.
- REGENERON PHARMACEUTICALS, INC. repayment of long-term debt, long-term lease obligation, and capital security for the quarter ending 2018-06-30 was $0.00, a 100.00% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. repayment of long-term debt, long-term lease obligation, and capital security for the quarter ending 2018-03-31 was $0.00, a 100.00% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. repayment of long-term debt, long-term lease obligation, and capital security for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- REGENERON PHARMACEUTICALS, INC. repayment of long-term debt, long-term lease obligation, and capital security for fiscal 2017 was $19.90M, a 39.33% decline from fiscal 2016.
- REGENERON PHARMACEUTICALS, INC. repayment of long-term debt, long-term lease obligation, and capital security for fiscal 2016 was $32.80M, a 2324.24% increase from fiscal 2015.
- REGENERON PHARMACEUTICALS, INC. repayment of long-term debt, long-term lease obligation, and capital security for fiscal 2015 was $1.35M.
| Period end | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security 3 month | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security 6 month | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security 9 month | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security 12 month | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security 12 month as first filed |
|---|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-07 | $0.00 derived: sum of 2 quarters · filed 2019-02-07 | $0.00 derived: sum of 3 quarters · filed 2019-02-07 | $0.00 10-K · filed 2019-02-07 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $0.00 derived: sum of 2 quarters · filed 2018-11-06 | $0.00 10-Q · filed 2018-11-06 | -$25.00K derived: sum of 4 quarters · filed 2019-02-07 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $0.00 10-Q · filed 2018-08-02 | -$25.00K derived: sum of 3 quarters · filed 2019-02-07 | -$25.00K derived: sum of 4 quarters · filed 2019-02-07 | |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-03 | -$25.00K derived: sum of 2 quarters · filed 2019-02-07 | -$25.00K derived: sum of 3 quarters · filed 2019-02-07 | $7.04M derived: sum of 4 quarters · filed 2019-02-07 | |
| 2017-12-31 | -$25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-07 | -$25.00K derived: sum of 2 quarters · filed 2019-02-07 | $7.04M derived: sum of 3 quarters · filed 2019-02-07 | $19.90M 10-K · filed 2019-02-07 | $19.93M 10-K · filed 2018-02-08 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $7.06M derived: sum of 2 quarters · filed 2018-11-06 | $19.93M 10-Q · filed 2018-11-06 | $50.87M derived: sum of 4 quarters · filed 2019-02-07 | |
| 2017-06-30 | $7.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $19.93M 10-Q · filed 2018-08-02 | $50.87M derived: sum of 3 quarters · filed 2019-02-07 | $51.51M derived: sum of 4 quarters · filed 2019-02-07 | |
| 2017-03-31 | $12.86M 10-Q · filed 2018-05-03 | $43.81M derived: sum of 2 quarters · filed 2019-02-07 | $44.45M derived: sum of 3 quarters · filed 2019-02-07 | ||
| 2016-12-31 | $30.95M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-07 | $31.59M derived: sum of 2 quarters · filed 2019-02-07 | $32.80M 10-K · filed 2019-02-07 | $32.77M 10-K · filed 2018-02-08 | |
| 2016-09-30 | $640.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $1.85M 10-Q · filed 2017-11-08 | |||
| 2016-06-30 | $1.21M 10-Q · filed 2017-08-03 | ||||
| 2015-12-31 | $1.35M 10-K · filed 2018-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |